Dr. Garfield D. Ramdeen, MD

Dr. Ramdeen practices at University of New Mexico Hospital in Albuquerque, New Mexico, part of The University of New Mexico.

Dr. Ramdeen's NPI, 1922191022, was assigned on October 2, 2006. Dr. Ramdeen holds New Mexico license 98-141.

Dr. Ramdeen's primary practice is University of New Mexico Hospital, at 2211 Lomas Boulevard NE, Albuquerque, NM 87106 in Bernalillo County. The practice phone is (505) 272-2111.

Dr. Ramdeen's primary practice is University of New Mexico Hospital in Albuquerque, New Mexico, part of The University of New Mexico. The medical group on file is UNM Medical Group, Inc. Dmand AI also links Dr. Ramdeen to 2 more dialysis centers and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ramdeen practices, 3 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Ramdeen's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dmand AI has Dr. Ramdeen's licenses on file in 2 states: New Mexico and Alabama.

CMS data shows 127 Medicare services from Dr. Ramdeen across 3 procedure codes in 2024, for 77 Medicare patients. Medicare paid $8,971 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 77 Medicare patients who saw Dr. Ramdeen in 2024. The largest group is 65 to 74, with 33 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 62% are also on Medicaid. Their average risk score is 5.82, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ramdeen's median patient age at 67, with 40% women.

In 2024, Dr. Ramdeen wrote 113 Medicare Part D claims for 26 patients. 95% of them were for generic drugs. CMS names the drug for 37 of them, across 3 drugs with 11 or more claims each, at $3,241 in total drug cost. In 2023, CMS named 249 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Ramdeen for performance year 2024, reported as part of a group. Dr. Ramdeen accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 223 general payments to Dr. Ramdeen from 29 drug and device companies from 2016 to 2023. Food and beverage make up the largest share, 100% of the total. OPKO Pharmaceuticals, LLC paid the most, $583.